A population-based cohort study of 211,200 individuals from the Apolipoprotein-Related Mortality Risk (AMORIS) cohort found that high levels of glucose and triglycerides, and low levels of high-density lipoprotein (HDL-C), were associated with an increased risk of depression, anxiety, and stress-related disorders. These associations were consistent across genders and types of disorders. The study also found that individuals with depression, anxiety, or stress-related disorders had higher levels of glucose, triglycerides, and total cholesterol 20 years before diagnosis, and higher levels of apolipoprotein A-I and apolipoprotein B 10 years before diagnosis, compared to controls. The findings suggest that metabolic dysregulation may play a role in the development of common psychiatric disorders. The study highlights the importance of monitoring individuals with metabolic dysregulations for the prevention and early diagnosis of psychiatric disorders. The results indicate that metabolic biomarkers such as glucose, triglycerides, and HDL-C may be useful in assessing the risk of psychiatric disorders. The study also found that high levels of low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B, and the ApoB/ApoA-I ratio were associated with a lower risk of these disorders. The study's findings support the need for further research to explore the potential of metabolic biomarkers in the prevention and management of psychiatric disorders.A population-based cohort study of 211,200 individuals from the Apolipoprotein-Related Mortality Risk (AMORIS) cohort found that high levels of glucose and triglycerides, and low levels of high-density lipoprotein (HDL-C), were associated with an increased risk of depression, anxiety, and stress-related disorders. These associations were consistent across genders and types of disorders. The study also found that individuals with depression, anxiety, or stress-related disorders had higher levels of glucose, triglycerides, and total cholesterol 20 years before diagnosis, and higher levels of apolipoprotein A-I and apolipoprotein B 10 years before diagnosis, compared to controls. The findings suggest that metabolic dysregulation may play a role in the development of common psychiatric disorders. The study highlights the importance of monitoring individuals with metabolic dysregulations for the prevention and early diagnosis of psychiatric disorders. The results indicate that metabolic biomarkers such as glucose, triglycerides, and HDL-C may be useful in assessing the risk of psychiatric disorders. The study also found that high levels of low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B, and the ApoB/ApoA-I ratio were associated with a lower risk of these disorders. The study's findings support the need for further research to explore the potential of metabolic biomarkers in the prevention and management of psychiatric disorders.